129 related articles for article (PubMed ID: 27012210)
1. Curcumin suppresses 4-hydroxytamoxifen resistance in breast cancer cells by targeting SLUG/Hexokinase 2 pathway.
Geng C; Li J; Ding F; Wu G; Yang Q; Sun Y; Zhang Z; Dong T; Tian X
Biochem Biophys Res Commun; 2016 Apr; 473(1):147-153. PubMed ID: 27012210
[TBL] [Abstract][Full Text] [Related]
2. Elevated Hexokinase II Expression Confers Acquired Resistance to 4-Hydroxytamoxifen in Breast Cancer Cells.
Liu X; Miao W; Huang M; Li L; Dai X; Wang Y
Mol Cell Proteomics; 2019 Nov; 18(11):2273-2284. PubMed ID: 31519767
[TBL] [Abstract][Full Text] [Related]
3. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
[TBL] [Abstract][Full Text] [Related]
4. Slug contributes to cancer progression by direct regulation of ERα signaling pathway.
Li Y; Wu Y; Abbatiello TC; Wu WL; Kim JR; Sarkissyan M; Sarkissyan S; Chung SS; Elshimali Y; Vadgama JV
Int J Oncol; 2015 Apr; 46(4):1461-72. PubMed ID: 25652255
[TBL] [Abstract][Full Text] [Related]
5. SLUG-induced elevation of D1 cyclin in breast cancer cells through the inhibition of its ubiquitination.
Mittal MK; Singh K; Misra S; Chaudhuri G
J Biol Chem; 2011 Jan; 286(1):469-79. PubMed ID: 21044962
[TBL] [Abstract][Full Text] [Related]
6. PAC down-regulates estrogen receptor alpha and suppresses epithelial-to-mesenchymal transition in breast cancer cells.
Al-Howail HA; Hakami HA; Al-Otaibi B; Al-Mazrou A; Daghestani MH; Al-Jammaz I; Al-Khalaf HH; Aboussekhra A
BMC Cancer; 2016 Jul; 16():540. PubMed ID: 27465411
[TBL] [Abstract][Full Text] [Related]
7. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
Devulapally R; Sekar TV; Paulmurugan R
Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
[TBL] [Abstract][Full Text] [Related]
8. A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in ERα-Negative Breast Cancer Cells.
Kala R; Tollefsbol TO
PLoS One; 2016; 11(5):e0155057. PubMed ID: 27159275
[TBL] [Abstract][Full Text] [Related]
9. ERalpha suppresses slug expression directly by transcriptional repression.
Ye Y; Xiao Y; Wang W; Yearsley K; Gao JX; Barsky SH
Biochem J; 2008 Dec; 416(2):179-87. PubMed ID: 18588516
[TBL] [Abstract][Full Text] [Related]
10. ERalpha signaling through slug regulates E-cadherin and EMT.
Ye Y; Xiao Y; Wang W; Yearsley K; Gao JX; Shetuni B; Barsky SH
Oncogene; 2010 Mar; 29(10):1451-62. PubMed ID: 20101232
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Metabolism as a Therapeutic Option for Tamoxifen-Resistant Breast Cancer Cells.
Steifensand F; Gallwas J; Bauerschmitz G; Gründker C
Cells; 2021 Sep; 10(9):. PubMed ID: 34572047
[TBL] [Abstract][Full Text] [Related]
12. Regulation of BRCA2 gene expression by the SLUG repressor protein in human breast cells.
Tripathi MK; Misra S; Khedkar SV; Hamilton N; Irvin-Wilson C; Sharan C; Sealy L; Chaudhuri G
J Biol Chem; 2005 Apr; 280(17):17163-71. PubMed ID: 15734731
[TBL] [Abstract][Full Text] [Related]
13. Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner.
Shao S; Zhao X; Zhang X; Luo M; Zuo X; Huang S; Wang Y; Gu S; Zhao X
Mol Cancer; 2015 Feb; 14(1):28. PubMed ID: 25645291
[TBL] [Abstract][Full Text] [Related]
14. HES1 promotes breast cancer stem cells by elevating Slug in triple-negative breast cancer.
Li X; Li Y; Du X; Wang X; Guan S; Cao Y; Jin F; Li F
Int J Biol Sci; 2021; 17(1):247-258. PubMed ID: 33390847
[TBL] [Abstract][Full Text] [Related]
15. Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene.
Yan Y; Li XQ; Duan JL; Bao CJ; Cui YN; Su ZB; Xu JR; Luo Q; Chen M; Xie Y; Lu WL
Int J Nanomedicine; 2019; 14():3645-3667. PubMed ID: 31190817
[No Abstract] [Full Text] [Related]
16. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial Cytotoxic Effects of 2,3-Dichloro-5,8-dimethoxy-1,4-naphthoquinone and 4-hydroxytamoxifen in Triple-negative Breast Cancer Cell Lines.
Robinson AGJ; Kanaan YM; Copeland RL
Anticancer Res; 2020 Dec; 40(12):6623-6635. PubMed ID: 33288557
[TBL] [Abstract][Full Text] [Related]
18. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
19. [Knockdown of hexokinase 2 (HK2) inhibits breast cancer cell proliferation and reduces their resistance to fluorouracil].
Wang J; Tao M; Wang T; Wang Z; Xiao J; Ding S; Chen R
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Aug; 37(8):722-727. PubMed ID: 34236032
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
